{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:28:28Z","timestamp":1793413708372,"version":"4.5.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2022,9,1]]},"DOI":"10.1001\/jamacardio.2022.2333","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T11:01:05Z","timestamp":1659524465000},"page":"955","source":"Crossref","is-referenced-by-count":70,"title":["Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease"],"prefix":"10.1001","volume":"7","author":[{"given":"Arjen J.","family":"Cupido","sequence":"first","affiliation":[{"name":"Amsterdam UMC location, University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Amsterdam, the Netherlands"},{"name":"Division of Heart & Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands"},{"name":"Division of Cardiology, Department of Medicine, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens F.","family":"Reeskamp","sequence":"additional","affiliation":[{"name":"Amsterdam UMC location, University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroon D.","family":"Hingorani","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, United Kingdom"},{"name":"Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom"},{"name":"UCL British Heart Foundation Research Accelerator, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Finan","sequence":"additional","affiliation":[{"name":"Division of Heart & Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands"},{"name":"Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, United Kingdom"},{"name":"Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom"},{"name":"UCL British Heart Foundation Research Accelerator, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W.","family":"Asselbergs","sequence":"additional","affiliation":[{"name":"Division of Heart & Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands"},{"name":"Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, United Kingdom"},{"name":"Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[{"name":"Amsterdam UMC location, University of Amsterdam, Department of Vascular Medicine, Amsterdam, the Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Atherosclerosis & Ischemic Syndromes, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amand F.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Division of Heart & Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands"},{"name":"Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, United Kingdom"},{"name":"Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom"},{"name":"UCL British Heart Foundation Research Accelerator, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"14","key":"hoi220039r1","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jama.2019.14120","article-title":"Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease.","volume":"322","author":"Ference","year":"2019","journal-title":"JAMA"},{"issue":"9753","key":"hoi220039r2","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"hoi220039r3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011748.pub3","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.","volume":"10","author":"Schmidt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"August","key":"hoi220039r4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"hoi220039r5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jacl.2020.11.004","article-title":"PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization.","volume":"15","author":"Zafrir","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"1","key":"hoi220039r6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40256-020-00411-3","article-title":"PCSK9 inhibitors in a German single-center clinical practice: real-world treatment of patients at high cardiovascular risk over 68 weeks.","volume":"21","author":"Hollstein","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"hoi220039r7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study.","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"hoi220039r8","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s12325-020-01285-2","article-title":"Proportion of high-risk\/very high-risk patients in Europe with low-density lipoprotein cholesterol at target according to European guidelines: a systematic review.","volume":"37","author":"Bruckert","year":"2020","journal-title":"Adv Ther"},{"issue":"2","key":"hoi220039r9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/eurheartj\/ehp399","article-title":"Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.","volume":"31","author":"Chapman","year":"2010","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi220039r10","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1038\/s41467-021-25703-3","article-title":"Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.","volume":"12","author":"Schmidt","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"hoi220039r12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/FJC.0000000000001093","article-title":"Advancing beyond failed high-density lipoprotein clinical trials to pharmacogenetic studies of ADCY9 and cholesterol ester transfer protein inhibition.","volume":"78","author":"Black","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"hoi220039r13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamacardio.2021.3728","article-title":"Long-term benefits and harms associated with genetic cholesteryl ester transfer protein deficiency in the general population.","volume":"7","author":"Nordestgaard","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"8","key":"hoi220039r14","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Mendelian randomization: using genes as instruments for making causal inferences in epidemiology.","volume":"27","author":"Lawlor","year":"2008","journal-title":"Stat Med"},{"issue":"4","key":"hoi220039r15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/ije\/dyz161","article-title":"Factorial Mendelian randomization: using genetic variants to assess interactions.","volume":"49","author":"Rees","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"5","key":"hoi220039r16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.117.001992","article-title":"Genetic regulation of PCSK9 (proprotein convertase subtilisin\/kexin type 9) plasma levels and its impact on atherosclerotic vascular disease phenotypes.","volume":"11","author":"Pott","year":"2018","journal-title":"Circ Genom Precis Med"},{"issue":"3","key":"hoi220039r17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41431-018-0301-5","article-title":"Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile.","volume":"27","author":"Blauw","year":"2019","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"hoi220039r18","doi-asserted-by":"publisher","first-page":"11008","DOI":"10.1038\/s41598-017-10812-1","article-title":"Genome-wide analysis of health-related biomarkers in the UK Household Longitudinal Study reveals novel associations.","volume":"7","author":"Prins","year":"2017","journal-title":"Sci Rep"},{"key":"hoi220039r19","doi-asserted-by":"publisher","first-page":"11122","DOI":"10.1038\/ncomms11122","article-title":"Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA.","volume":"7","author":"Kettunen","year":"2016","journal-title":"Nat Commun"},{"issue":"10","key":"hoi220039r20","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"issue":"7726","key":"hoi220039r21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data.","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"issue":"6","key":"hoi220039r22","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/ije\/dyw123","article-title":"Comparison of variance estimators for meta-analysis of instrumental variable estimates.","volume":"45","author":"Schmidt","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"4","key":"hoi220039r25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial.","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"10","key":"hoi220039r26","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk.","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"hoi220039r27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41569-019-0157-6","article-title":"What is \u2018LDL cholesterol\u2019?","volume":"16","author":"Holmes","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"hoi220039r28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1194\/jlr.M032615","article-title":"Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.","volume":"54","author":"Davidson","year":"2013","journal-title":"J Lipid Res"},{"issue":"13","key":"hoi220039r29","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease.","volume":"377","author":"HPS3\/TIMI55\u2013REVEAL Collaborative Group","year":"2017","journal-title":"N Engl J Med"},{"issue":"32","key":"hoi220039r30","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"3","key":"hoi220039r31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ophtha.2018.09.045","article-title":"Increased high-density lipoprotein levels associated with age-related macular degeneration: evidence from the EYE-RISK and European Eye Epidemiology Consortia.","volume":"126","author":"Colijn","year":"2019","journal-title":"Ophthalmology"},{"issue":"21","key":"hoi220039r32","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"9716","key":"hoi220039r33","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"hoi220039r34","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes.","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi220039r35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study.","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"hoi220039r36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2337\/dc17-1464","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-Years.","volume":"41","author":"de Carvalho","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"hoi220039r37","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2337\/dc19-2204","article-title":"Dalcetrapib reduces risk of new-onset diabetes in patients with coronary heart disease.","volume":"43","author":"Schwartz","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"hoi220039r38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000943","article-title":"Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial.","volume":"8","author":"Menon","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"1","key":"hoi220039r39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jacl.2017.10.023","article-title":"Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: a population-based study.","volume":"12","author":"Christen","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"9822","key":"hoi220039r40","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis.","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"hoi220039r41","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","article-title":"Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression.","volume":"53","author":"V\u00f5sa","year":"2021","journal-title":"Nat Genet"},{"key":"hoi220039r42","doi-asserted-by":"publisher","first-page":"k601","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians.","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"issue":"7003","key":"hoi220039r43","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/bmj.311.7003.485","article-title":"Absence of evidence is not evidence of absence.","volume":"311","author":"Altman","year":"1995","journal-title":"BMJ"},{"key":"hoi220039r11","unstructured":"ClinicalTrials.gov. Randomized study to evaluate the effect of obicetrapib on top of maximum tolerated lipid-modifying therapies (BROADWAY). Accessed February 17, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05142722?term=obicetrapib&draw=2&rank=1"},{"key":"hoi220039r23","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Published online 2019. https:\/\/www.r-project.org\/"},{"key":"hoi220039r24","unstructured":"Wickham? H; Springer. ggplot2: Elegant graphics for data analysis. Accessed July 2, 2020. https:\/\/www.springer.com\/gp\/book\/9783319242750"},{"key":"hoi220039r44","unstructured":"National Institutes of Health. All of Us Research Program overview. Accessed May 16, 2022. https:\/\/allofus.nih.gov\/about\/program-overview"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2795049\/jamacardiology_cupido_2022_oi_220039_1663082210.22672.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T11:01:59Z","timestamp":1663153319000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2795049"}},"subtitle":["A Factorial Mendelian Randomization Study"],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2022.2333","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}